- Conditions
- Diffuse Intrinsic Pontine Glioma
- Interventions
- Tumor Lysate Vaccine, Imiquimod, Radiation therapy
- Biological · Drug · Radiation
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 3 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2281–2304
of 196,835
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Sjogren Syndrome
- Interventions
- VAY736, Placebo
- Biological · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 275 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 13
- States / cities
- Van Nuys, California • Tamarac, Florida • Indianapolis, Indiana + 10 more
- Conditions
- AL Amyloidosis
- Interventions
- Bortezomib, Cyclophosphamide, Dexamethasone, Isatuximab
- Drug · Biological
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 6
- States / cities
- Orange, California • Atlanta, Georgia • Detroit, Michigan + 2 more
- Conditions
- Healthy
- Interventions
- [14C]PF-05221304
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 45 Years · Male only
- Enrollment
- 6 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Breast Cancer
- Interventions
- Post-visit patient text messaging, Default pended order, High risk bidirectional post-visit text messaging
- Behavioral
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 40 Years to 74 Years · Female only
- Enrollment
- 21,123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 2
- States / cities
- Cleveland, Ohio • Philadelphia, Pennsylvania
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Symptomatic COVID-19 Infection Laboratory-Confirmed
- Interventions
- SARS-CoV-2 Antigen-specific Cytotoxic T-lymphocytes
- Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- COVID-19
- Interventions
- Intranasal lavage with hypochlorous acid solution
- Other
- Lead sponsor
- Monique Lisa Abner
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 88 participants
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Reading, Pennsylvania
- Conditions
- Alzheimer Disease
- Interventions
- Mediterranean Diet, Study Supplement, Low-fat Diet
- Behavioral · Dietary Supplement
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 209 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Lymphoma, Non-Hodgkin, Relapsed Diffuse Large B Cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma, Transformed Indolent Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
- Interventions
- Epcoritamab
- Drug
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Acute Leukemia, Myelodysplastic Syndromes
- Interventions
- ONO-7475 3mg once daily, ONO-7475 6mg once daily, ONO-7475 10mg once daily, ONO-7475 6mg + Venetoclax (70-400mg)
- Drug
- Lead sponsor
- Ono Pharmaceutical Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 16
- States / cities
- Los Angeles, California • North Haven, Connecticut • Gainesville, Florida + 12 more
- Conditions
- Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Cognitive Impairment
- Interventions
- No Intervention, donanemab
- Other · Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 60 Years to 90 Years
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Irvine, California • Bradenton, Florida + 19 more
- Conditions
- Healthy
- Interventions
- Lesinurad 400 mg (manufactured at Site 1), Lesinurad 400 mg (manufactured at Site 2)
- Drug
- Lead sponsor
- Ardea Biosciences, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 54 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Kidney Diseases, Chronic Renal Insufficiency, End-Stage Renal Disease
- Interventions
- Sevelamer carbonate (Renvela®), Sevelamer hydrochloride (Renagel®)
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 217 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Gadsden, Alabama • Mission Hills, California + 26 more
- Conditions
- Major Depressive Disorder
- Interventions
- Sham TMS + Cognitive therapy, Active TMS + Cognitive therapy
- Device
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Alzheimer's Disease
- Interventions
- PF-04447943, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 191 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 22
- States / cities
- Northport, Alabama • Costa Mesa, California • Glendale, California + 18 more
- Conditions
- Aneurysmal Subarachnoid Hemorrhage, Cerebral Vasospasm
- Interventions
- Placebos for acetaminophen and N-acetylcysteine, APAP 1 gm every 6 hours and N-acetylcysteine placebo, NAC IV infusion at 0.5 gm hourly and APAP placebo, APAP 1 gm q6 hours, plus NAC IV infusion at 0.5 gm hourly, APAP 1.5 gm q6 hours, plus NAC IV infusion at 0.5 gm hourly
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 20 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2023
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- temozolomide, neoadjuvant therapy, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2018
- U.S. locations
- 38
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 31 more
- Conditions
- Pelvic Organ Prolapse
- Interventions
- MatriStem Pelvic Floor Matrix, native tissue repair
- Device · Procedure
- Lead sponsor
- Integra LifeSciences Corporation
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 161 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 13
- States / cities
- Stanford, California • Weston, Florida • Grand Rapids, Michigan + 10 more
- Conditions
- Diabetes Mellitus Type 2
- Interventions
- Placebo, RO5027838, RO5093151
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 35 Years to 65 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 2
- States / cities
- Chula Vista, California • Miami, Florida
- Conditions
- Safety of Short Term Creatine Hydrochloride Dosing
- Interventions
- creatine supplementation
- Dietary Supplement
- Lead sponsor
- Vireo Systems, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Raritan, New Jersey
- Conditions
- Aggression, Post Traumatic Stress Disorders
- Interventions
- Strength at Home Couples Group, Supportive Group Therapy
- Behavioral
- Lead sponsor
- Boston VA Research Institute, Inc.
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 156 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2014
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Providence, Rhode Island
- Conditions
- Non-Hodgkin Lymphoma
- Interventions
- SGN-40 (anti-huCD40 mAb)
- Drug
- Lead sponsor
- Seagen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • Stanford, California • Miami, Florida + 2 more
- Conditions
- Contrast Induced Acute Kidney Injury
- Interventions
- Isuzinaxib (APX-115), Placebo
- Drug
- Lead sponsor
- Aptabio Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 218 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Menstruation
- Interventions
- Tampax menstrual cup, Other menstrual cup
- Device
- Lead sponsor
- Procter and Gamble
- Industry
- Eligibility
- 18 Years to 55 Years · Female only
- Enrollment
- 65 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio